Stay updated on VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial page.

Latest updates to the VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial page
- Check2 days agoChange DetectedThe study record no longer displays the 2019 NIH grant/contract identifier, and the site revision label changes from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check9 days agoChange DetectedThe clinical trial record for the completed Phase 2 VIS649 study in IgA nephropathy is displayed, including study details, results, participant criteria, and supporting documents.SummaryDifference100%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 on the page displaying a 403 error.SummaryDifference0.2%

- Check30 days agoChange DetectedA banner announces an NIH website transition and says the agency is using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check37 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check44 days agoChange DetectedThe revision label in the site footer changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

Stay in the know with updates to VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial page.